Histamine glutarimide
- Generic Name
- Histamine glutarimide
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N3O2
- CAS Number
- 1464897-15-1
- Unique Ingredient Identifier
- VOM9DP10M3
- Background
Histamine glutarimide is under investigation in clinical trial NCT03450434 (XC8 in the Treatment of Patients With Bronchial Asthma).
Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 252
- Registration Number
- NCT06379542
- Locations
- 🇷🇺
PiterKlinika LLC, Saint Petersburg, Russian Federation
🇷🇺City Pediatric Outpatient Clinic number 5, Perm, Russian Federation
🇷🇺ArsVite North-West, LLC, Saint Petersburg, Russian Federation
Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 24
- Registration Number
- NCT05558462
- Locations
- 🇷🇺
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 24
- Registration Number
- NCT05294250
- Locations
- 🇷🇺
Limited Liability Company "Research Center Eco-Security", Saint Petersburg, Russian Federation
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- PHARMENTERPRISES LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03441815
- Locations
- 🇷🇺
SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.